$298 Million is the total value of Stonepine Capital Management, LLC's 22 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 57.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMYT | Sell | AMRYT PHARMA PLC - SPNR ADRsponsored ads | $91,534,479 | +98.0% | 6,278,085 | -0.9% | 30.70% | +57.8% |
| GLPG | Buy | GALAPAGOS NV-SPON ADRspon adr | $30,227,647 | +249.6% | 782,289 | +301.5% | 10.14% | +178.7% |
| CTIC | Buy | CTI BIOPHARMA CORP | $27,449,831 | -7.4% | 6,535,674 | +32.5% | 9.21% | -26.2% |
| ADMA | Buy | ADMA BIOLOGICS INC | $25,360,194 | -5.8% | 7,661,690 | +10.4% | 8.50% | -24.9% |
| Sell | QUIDELORTHO CORP | $24,863,326 | -3.3% | 279,081 | -7.0% | 8.34% | -22.9% | |
| Sell | XERIS BIOPHARMA HOLDINGS INC | $14,083,534 | -5.4% | 8,640,205 | -22.8% | 4.72% | -24.6% | |
| Buy | MAXCYTE INC | $13,400,096 | +798.0% | 2,707,090 | +890.6% | 4.49% | +615.6% | |
| Buy | THIRD HARMONIC BIO INC | $12,903,819 | +48.9% | 3,131,995 | +55.4% | 4.33% | +18.7% | |
| LIFE | New | ATYR PHARMA INC | $10,134,016 | – | 4,825,722 | +100.0% | 3.40% | – |
| XOMA | Buy | XOMA CORP | $6,715,007 | +466.2% | 318,096 | +393.5% | 2.25% | +351.3% |
| CSTL | Buy | CASTLE BIOSCIENCES INC | $6,653,916 | +58.6% | 292,866 | +64.3% | 2.23% | +26.5% |
| URGN | Sell | UROGEN PHARMA LTD | $6,482,183 | -44.0% | 701,535 | -46.2% | 2.17% | -55.4% |
| RZLT | Buy | REZOLUTE INC | $5,928,286 | -5.2% | 3,087,649 | +2.2% | 1.99% | -24.4% |
| EOLS | Sell | EVOLUS INC | $4,896,606 | -21.9% | 578,795 | -30.6% | 1.64% | -37.7% |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $4,086,051 | – | 416,519 | +100.0% | 1.37% | – |
| APEN | Sell | APOLLO ENDOSURGERY INC | $3,670,400 | -90.1% | 370,000 | -90.1% | 1.23% | -92.1% |
| TVTX | New | TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $2,968,792 | – | 132,005 | +100.0% | 1.00% | – |
| XGN | Buy | EXAGEN INC | $2,520,090 | +22.9% | 1,037,074 | +21.4% | 0.84% | -2.0% |
| AVIR | New | ATEA PHARMACEUTICALS INC | $2,293,102 | – | 684,508 | +100.0% | 0.77% | – |
| SCYX | New | SCYNEXIS INC | $1,350,000 | – | 450,000 | +100.0% | 0.45% | – |
| New | CONFORMIS INC | $648,268 | – | 402,651 | +100.0% | 0.22% | – | |
| CDTX | New | CIDARA THERAPEUTICS INC | $1,270 | – | 1,000 | +100.0% | 0.00% | – |
| OPTN | Exit | OPTINOSE INC | $0 | – | -508,284 | -100.0% | -0.40% | – |
| Exit | OMNIAB INC | $0 | – | -354,266 | -100.0% | -0.54% | – | |
| MIRM | Exit | MIRUM PHARMACEUTICALS INC | $0 | – | -108,769 | -100.0% | -0.89% | – |
| CFMS | Exit | CONFORMIS INC | $0 | – | -748,194 | -100.0% | -1.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.